Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, or CGRP, a molecule that is involved in migraine attacks.
| Manufacturer | Novartis |
|---|---|
| Brand Name | Aimovig |
| Dosage | The recommended dosage of Aimovig® is 70 mg once monthly; some patients may benefit from 140 mg once monthly OR Used as directed |
| Dosage Form | pen |
| Size | 1 PRE-FILLED PEN |
| Active Ingredients | erenumab |
| Side Effects | N/A |
| Contraindications | N/A |
Write Your Own Review